ArticleScientific reports2025
ALL diagnosis: can efficiency and transparency coexist? An explainble deep learning approach.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Applications of Artificial Intelligence in Cancer Diagnosis and Treatment.Cancer medicine · 2026Review
- Relative devaluation in AI transitions: an organizational behavior perspective on career sustainability beyond well-being.Frontiers in psychology · 2026Review
- More than just a heatmap: elevating XAI with rigorous evaluation metrics.Frontiers in medical technology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute Lymphoblastic Leukemia (ALL) is a life-threatening malignancy characterized by its aggressive progression and detrimental effects on the hematopoietic system. Early and accurate diagnosis is paramount to optimizing therapeutic interventions and improving clinical outcomes. This study introduces a novel diagnostic framework that synergizes the EfficientNet-B7 architecture with Explainable Artificial Intelligence (XAI) methodologies to address challenges in performance, computational efficiency, and explainability. The proposed model achieves improved diagnostic performance, with accuracies exceeding 96% on the Taleqani Hospital dataset and 95.50% on the C-NMC-19 and Multi-Cancer datasets. Rigorous evaluation across multiple metrics-including Area Under the Curve (AUC), mean Average Precision (mAP), Accuracy, Precision, Recall, and F1-score-demonstrates the model's robustness and establishes its superiority over state-of-the-art architectures namely VGG-19, InceptionResNetV2, ResNet50, DenseNet50 and AlexNet . Furthermore, the framework significantly reduces computational overhead, achieving up to 40% faster inference times, thereby enhancing its clinical applicability. To address the opacity inherent in Deep learning (DL) models, the framework integrates advanced XAI techniques, including Gradient-weighted Class Activation Mapping (Grad-CAM), Class Activation Mapping (CAM), Local Interpretable Model-Agnostic Explanations (LIME), and Integrated Gradients (IG), providing transparent and explainable insights into model predictions. This fusion of high diagnostic precision, computational efficiency, and explainability positions the proposed framework as a transformative tool for ALL diagnosis, bridging the gap between cutting-edge AI technologies and practical clinical deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.